AstraZeneca's cancer drug Lynparza, when combined with bevacizumab, succesfully improved the amount of time patients with ovarian cancer lived without disase progression when compared with bevacizumab alone. "AstraZeneca's Lynparza Successful in Second Ovarian Cancer Phase 3 Study" at 0630 GMT on Aug. 14, in the fourth paragraph, misstated the name of the drug that was combined with Lynparza. It is bevacizumab, not olaparib.

(END) Dow Jones Newswires

August 16, 2019 09:11 ET (13:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Merck Charts.